

Performance Against 70 Day Benchmark

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Reasons for delay correspond to:
14/SW/1085	161878	NCRN - 3159	07/09/2015	15/08/2016	Neither
14/NI/1113	155739	CONSISTENT CTO	06/08/2015	02/11/2015	Sponsor
14/NI/1114	163144	CELTIC	06/08/2015	12/10/2015	Benchmark Met
13/LO/1207	86810	Stereotactic radiotherapy for wet AMD (STAR)	29/09/2015	14/01/2016	Sponsor
13/EE/0202	89944	Inter-B-NHL Ritux 2010	07/10/2015		Neither
15/SW/0230	181260	The Bristol Twin (BRIT) Study	01/10/2015	30/10/2015	Benchmark Met
15/LO/1166	178877	Efficacy and Safety of RTH258 versus Aflibercept	08/10/2015	26/11/2015	Benchmark Met
14/LO/2129	163516	The VIOLET study	09/10/2015	27/10/2015	Benchmark Met
15/LO/0273	149700	M14-011: Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard	14/10/2015	09/02/2016	Sponsor
15/LO/0900	167412	630-0012 Pulmonx LIBERATE Study	23/10/2015	17/02/2016	Neither
15/SC/0311	181166	VEST III PMS clinical protocol	13/10/2015	11/11/2015	Benchmark Met
15/LO/0771	179095	APTITUDE: A phase II trial of Tocilizumab in antiTNF refractory patients with JIA associated uveitis	29/10/2015	20/11/2015	Benchmark Met
14/WA/1205	164410	SPICE III	26/10/2015	12/01/2016	Sponsor
15/LO/0324	138836	Improving sexual function after treatment for gynaecological cancer (SAFFRON)	05/11/2015		Sponsor
14/YH/1202	160376	PREVAIL NICU Study	11/11/2015	04/12/2015	Benchmark Met
14/SC/1312	156143	IMox study	20/11/2015	01/12/2015	Benchmark Met
15/NW/0631	185354	OKAH-193 Varicella vaccine study in the second year of life	12/11/2015	27/01/2016	Neither
15/EE/0100	163708	MK5172/ MK3682 with MK8742 or MK8408 in HCV GT1, GT2, and GT4 Infected Subjects	20/11/2015	04/12/2015	Benchmark Met
15/LO/0691	174324	Checkmate - 171	19/11/2015	10/12/2015	Benchmark Met
15/SC/0397	183591	An evaluation of the tolerance and acceptability of Neocate Junior, an amino acid based feed for children.	16/11/2015	15/04/2016	Neither
13/ES/0123	119188	NiCCC Trial (BIBF1120)	01/12/2015	29/02/2016	Neither

Performance Against 70 Day Benchmark

14/WA/1056	154468	AML 19	03/12/2015	03/12/2015	Benchmark Met
15/WS/0216	189003	BAX855 PUP	01/12/2015	05/01/2016	Benchmark Met
14/SC/1309	134909	The TEMPLATE Study	11/12/2015	15/01/2016	Benchmark Met
15/WA/0360	184197	The TARGET All Comer Clinical Trial	10/12/2015	17/12/2015	Benchmark Met
15/LO/0920	181642	SMTC11004: Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)	15/12/2015	04/02/2016	Benchmark Met
14/LO/1885	151063	EDIBLE v1.0	22/12/2015		Neither
15/SS/0186	190856	Protocol 083: MK5172A + Sofosbuvir +/-RBV in Cirrhotic GT3 Subjects (MK-5172-083)	19/01/2016	28/01/2016	Benchmark Met
15/WS/0121	173661	Propel 004 - MSB0010718C in NSCLC - EMR100070004:Phase III study of avelumab vs docetaxel in NSCLC - Javelin Lung 200	20/01/2016	10/03/2016	Benchmark Met
14/NE/0103	141927	A randomised double blind dose non-inferiority trial of aspirin in Lynch syndrome	14/01/2016	13/04/2016	Neither
15/SC/0603	114842	CCRN 2393 MAESTRO-OL	26/01/2016	01/03/2016	Benchmark Met
14/SC/1329	157664	STRIVE	27/01/2016		Neither
15/SW/0008	163427	The Bluebelle study (Phase B)	22/01/2016	01/03/2016	Benchmark Met
14/SC/1290	141516	TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia	27/01/2016	19/02/2016	Benchmark Met
14/WA/1118	159836	Postoperative adjuvant treatment for HPVpositive tumours (PATHOS)	01/02/2016	09/02/2016	Benchmark Met
15/NW/0416	167060	MUK8	02/02/2016	13/09/2016	NHS Provider
15/WM/0415	194417	PRIMAL	26/01/2016	23/02/2016	Benchmark Met
15/SC/0409	183061	OPHT 4170 (AMD) - SEQUOIA	03/02/2016	05/04/2016	Benchmark Met
15/EE/0405	189187	DIAB 4501	03/02/2016	01/05/2016	Sponsor
15/YH/0407	183603	Single Dose of MK0517 for Prevention of CINV in Paediatric Subjects	05/02/2016		Sponsor
15/EM/0300	180135	WO29636 - MPDL3280A in muscle invasive bladder cancer	26/01/2016	23/03/2016	Benchmark Met
15/SC/0456	174561	CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult	09/02/2016	24/03/2016	Benchmark Met
14/EM/1284	159662	Neo-AEGIS	07/01/2016	02/03/2016	Benchmark Met

Performance Against 70 Day Benchmark

14/YH/0128	150031	SaFaRI (SNS versus the FENIX MSA for adult FI)	15/02/2016	22/02/2016	Benchmark Met
15/LO/2098	182147	INTEREST: FP-1201-lyo for the treatment of ARDS	22/01/2016	04/04/2016	Sponsor
15/SW/0326	189007	ATLAS: JNJ56021927 (ARN509)	18/02/2016	15/03/2016	Benchmark Met
15/WM/0363	184648	COBALT: Study of Obeticholic Acid in Primary Biliary Cirrhosis (747-302)	26/01/2016	13/04/2016	NHS Provider
15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	08/03/2016		Neither
15/SW/0179	167604	Injectable Valve Implantation Trial (Invite)	16/02/2016	11/07/2016	Neither
14/LO/1206	154429	PLATFORM	22/02/2016	27/04/2016	Benchmark Met
15/EM/0437	184390	COLUMBUS-AMD	22/03/2016	01/06/2016	Sponsor
15/SC/0103	154496	SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer - 2	22/03/2016	27/04/2016	Benchmark Met
16/SW/0032	190476	My Health Tags - To Improve Taking Tablets For Heart Failure	23/03/2016	14/06/2016	Sponsor
15/NI/00243	191267	Study of CTX 4430 in Cystic Fibrosis Patients	31/03/2016	22/07/2016	Sponsor
15/LO/1464	174042	DARS	29/03/2016	23/09/2016	Neither
15/NE/0274	181026	EORTC 1320	24/03/2016	05/07/2016	Neither
14/EE/1293	164389	C-STICH	25/02/2016	16/06/2016	Both
14/LO/1644	137028	WT1TCR -002 Phase I/II study of genemodified WT1 TCR therapy in MDS & AML patient	28/04/2016	27/07/2016	Sponsor
15/LO/0141	169126	OPHT 3845	24/03/2016		Sponsor
15/LO/0413	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	12/05/2016	01/07/2016	Benchmark Met
15/LO/0710	177905	EMBARC:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer	17/05/2016		Neither
15/YH/0478	186697	REGENERATE: A Phase 3, DoubleBlind, Randomized, LongTerm, PlaceboControlled, Multicenter Study	26/05/2016		Neither
15/ES/0001	193859	GED-0301-CD-002 PhIII study for subjects with Active Crohn?s Disease (REVOLVE)	27/04/2016	09/09/2016	Sponsor
14/LO/2061	162162	Positioning in Macular Hole Surgery	07/06/2016		NHS Provider
15/EE/0464	183877	CRIT 4440	03/06/2016	14/09/2016	Sponsor
14/ES/1064	143994	LOGS - A randomised phase II/II study to assess the efficacy of Trametinib (GSK 1120212) in patients with	15/06/2016		Neither
15/WA/0316	182694	MyeChild 01	15/06/2016		Neither
14/NW/1110	149572	rEECur	29/03/2016		Both
14/SC/1416	156215	Immunoglobulin in the Treatment of Encephalitis (The IgNiTE study)	23/03/2016		Sponsor
15/LO/0769	155035	Left Atrial Appendage Occlusion Study III (LAAOS III)	27/07/2016		70 Days not yet reached
16/SW/0069	181429	Dynamic hormone diagnostics (ULTRADIAN)	29/02/2016		Sponsor
16/EE/0105	191013	ZOL-A trial	26/09/2016		70 Days not yet reached

Performance Against 70 Day Benchmark

HRA Approved Studies

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
16/HRA/0128	198232	NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER	25/02/2016	25/02/2016	11/03/2016	18/03/2016	15/04/2016	19/05/2016	25/05/2016	Benchmark Met
16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	07/04/2016	05/05/2016	06/07/2016	16/08/2016	17/08/2016	05/09/2016		Sponsor
15/YH/0550	177474	ICARE IBD Cancer and Serious Infections in Europe	16/06/2016	11/08/2016	16/06/2016	29/09/2016	29/09/2016			70 Days not yet reached

Performance Against 70 Day Benchmark

